Prostate Cancer MRI: Early Detection Guide

Prostate cancer is the most common cancer in men in the UK, with around 52,000 new diagnoses each year. One in 8 men will be diagnosed with prostate cancer during their lifetime. Multiparametric MRI (mpMRI) has fundamentally changed how prostate cancer is detected and diagnosed — since 2019, NICE guidelines recommend MRI before biopsy, and this approach has reduced unnecessary biopsies by roughly 25% while improving detection of clinically significant cancers.

If you have a raised PSA, a family history of prostate cancer, or symptoms that concern you, understanding how prostate MRI works — and what it can and cannot tell you — will help you make sense of the process.

Understanding Prostate Cancer

The prostate is a walnut-sized gland sitting below the bladder and in front of the rectum. It produces some of the fluid in semen. Prostate cancer typically grows slowly — many men live with it for years without knowing. But some prostate cancers are aggressive and need prompt treatment.

Key facts:

• Most common in men over 50, with incidence rising sharply after 65
• Black men have roughly double the risk of white men
• Men with a first-degree relative (father or brother) with prostate cancer have a 2-3x higher risk
• Prostate cancer causes around 12,000 deaths per year in the UK — the second most common cause of cancer death in men
• 5-year survival for all stages combined is around 87%, but for localised disease it is nearly 100%

The PSA Test: What It Means and Its Limitations

PSA (prostate-specific antigen) is a protein produced by the prostate. A raised PSA level can indicate prostate cancer, but it can also be raised by benign prostatic hyperplasia (BPH), prostatitis (infection/inflammation), urinary tract infection, recent ejaculation, vigorous exercise, or even cycling.

• Normal PSA is generally considered below 3 ng/mL for men under 60, and below 4 ng/mL for older men (though age-specific ranges vary)
• Around 75% of men with a PSA between 4-10 ng/mL do NOT have prostate cancer
• Some prostate cancers produce low levels of PSA, so a normal PSA does not completely rule out cancer
• PSA density (PSA divided by prostate volume on MRI) is a more useful measure than PSA alone

This is exactly why MRI has become so important — it helps distinguish between men who actually need a biopsy and those who can be monitored safely.

How Multiparametric MRI (mpMRI) Works

Multiparametric MRI combines several MRI techniques in one scan to build a detailed picture of the prostate. Each "parameter" provides different information:

• T2-weighted imaging — shows prostate anatomy in detail. Normal peripheral zone appears bright; cancer typically appears as a dark area. Also shows the prostate capsule, seminal vesicles, and surrounding structures.
• Diffusion-weighted imaging (DWI) and ADC mapping — measures how freely water molecules move. Cancer cells are tightly packed, restricting water movement. This shows up as a bright area on high b-value DWI and a dark area on the ADC map. DWI is considered the most sensitive sequence for prostate cancer detection.
• Dynamic contrast-enhanced (DCE) imaging — gadolinium contrast is injected and rapid images are taken. Cancerous tissue tends to enhance quickly and wash out early due to its abnormal blood vessels. This adds specificity to the other sequences.

PI-RADS Scoring

The radiologist scores any suspicious areas using the PI-RADS (Prostate Imaging Reporting and Data System) scale:

• PI-RADS 1 — very low suspicion. Clinically significant cancer is very unlikely.
• PI-RADS 2 — low suspicion. Clinically significant cancer is unlikely.
• PI-RADS 3 — intermediate. Clinically significant cancer is equivocal. Further assessment (biopsy or monitoring) may be needed depending on PSA and clinical context.
• PI-RADS 4 — high suspicion. Clinically significant cancer is likely. Biopsy is usually recommended.
• PI-RADS 5 — very high suspicion. Clinically significant cancer is highly likely. Biopsy is recommended.

Studies show that PI-RADS 4-5 lesions have roughly a 60-90% chance of containing clinically significant cancer on biopsy. PI-RADS 1-2 findings have a negative predictive value of around 90%, meaning MRI correctly identifies most men who do not need a biopsy.

What to Expect During a Prostate MRI

A prostate mpMRI takes 30-45 minutes. Here is what happens:

1. Preparation — you may be asked to use a small enema (Fleet/Microlax) 1-2 hours before the scan to empty the rectum. Gas and stool in the rectum can degrade image quality. Some centres also give an antispasmodic injection (Buscopan) to reduce bowel movement during the scan.
2. Positioning — you lie on your back. A surface coil (a flat pad) is placed over your pelvis. Most modern centres no longer use an endorectal coil (an internal probe) — external coils on 3T (Tesla) scanners provide excellent image quality without it.
3. Contrast injection — a cannula is placed in your arm for gadolinium contrast. This is injected part-way through the scan for the dynamic contrast-enhanced sequence.
4. The scan — multiple sequences run, each lasting 3-6 minutes. The usual loud knocking and buzzing. Headphones or earplugs provided.
5. Afterwards — you can leave immediately. The contrast is cleared by your kidneys within hours.

Specific Preparation

• Avoid ejaculation for 48-72 hours before the scan (ejaculation can temporarily alter prostate signal)
• You may need a recent kidney function blood test (eGFR) for the contrast injection
• Tell the team about any hip replacements — metal can cause image distortion
• Eat and drink normally (some centres ask you to have a light meal only)

What Prostate MRI Cannot Show

• Definitive cancer diagnosis — MRI identifies suspicious areas, but only a biopsy (tissue sample examined under a microscope) can confirm cancer and determine its grade (Gleason score/ISUP grade).
• All cancers — MRI misses around 10-15% of clinically significant cancers, particularly small tumours in the transition zone or anterior prostate. This is why PSA monitoring and clinical assessment remain important even after a normal MRI.
• Prostatitis vs cancer — inflammation can mimic cancer on MRI, leading to false-positive PI-RADS scores. Clinical history helps the radiologist interpret findings.
• Micro-metastases — MRI can detect local spread (through the capsule, into seminal vesicles) but cannot detect microscopic cancer spread to lymph nodes or bone. PET-CT (PSMA PET) is increasingly used for staging when spread is suspected.

The Diagnostic Pathway in the UK

1. PSA test — either through your GP, via the NHS Informed Choice programme (available to men over 50 who request it), or privately.
2. Raised PSA — if PSA is above the age-adjusted threshold, mpMRI is the next step (NICE guideline NG131).
3. MRI result — PI-RADS 1-2: reassurance, PSA monitoring. PI-RADS 3: discussion about biopsy vs monitoring depending on PSA density and clinical factors. PI-RADS 4-5: targeted biopsy recommended.
4. Biopsy — increasingly done as MRI-targeted transperineal biopsy (through the skin between scrotum and anus), which has lower infection risk than the older transrectal approach. Done under local anaesthetic, takes about 20 minutes.
5. Diagnosis confirmed — cancer is graded using the ISUP/Gleason scoring system. Grade Group 1 (Gleason 3+3=6) is low-risk. Grade Groups 2-5 represent increasing aggressiveness.

Treatment Pathways After Diagnosis

• Active surveillance — for low-risk, localised cancer (ISUP Grade Group 1). Regular PSA tests, MRI scans, and sometimes repeat biopsies to monitor. Around 30-40% of men on active surveillance will eventually need treatment, but many live with the cancer for decades without it affecting their health.
• Radical prostatectomy — surgical removal of the prostate, often robot-assisted (da Vinci). Around 10,000 performed annually in the UK. 10-year cancer-specific survival exceeds 95% for localised disease. Main risks: erectile dysfunction (40-70%), urinary incontinence (5-20% long-term).
• Radiotherapy — external beam (EBRT) or brachytherapy (radioactive seeds placed inside the prostate). Similar cancer control rates to surgery for localised disease.
• Focal therapy — newer treatments (HIFU, cryotherapy, irreversible electroporation) that treat only the cancerous area, aiming to preserve function. Available at specialist centres but not yet standard of care for all cases.
• Hormone therapy — for locally advanced or metastatic disease. Reduces testosterone to slow cancer growth.

Alternative and Complementary Tests

• PSA test — the starting point. Simple blood test. Available through your GP or privately through Lola Health.
• Free-to-total PSA ratio — helps distinguish BPH from cancer. A low free-to-total ratio is more suspicious.
• PHI (Prostate Health Index) — combines three PSA markers for improved specificity.
• Transrectal ultrasound (TRUS) — used to guide biopsies but poor at detecting cancer directly. Largely superseded by MRI for detection.
• PSMA PET-CT — the most sensitive staging test for prostate cancer. Detects metastatic disease that standard CT and bone scans miss. Increasingly used before radical treatment.

UK Statistics

• 52,000 new prostate cancer diagnoses per year in the UK
• 1 in 8 men will be diagnosed with prostate cancer in their lifetime
• 12,000 deaths per year — second most common cause of male cancer death
• 5-year survival for all stages: 87%. For localised disease: nearly 100%
• Introduction of pre-biopsy MRI has reduced unnecessary biopsies by approximately 25%
• Black men are twice as likely to develop prostate cancer as white men

Frequently Asked Questions

Related Articles

• Can an MRI Detect Cancer?
• MRI Scan for Kidney Problems
• MRI Scan for Hip Pain